Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ataxin-1-like (ATXN1L) is a chromatin-binding transcriptional corepressor protein and a paralog of Ataxin-1 (ATXN1). It enables chromatin binding and RNA binding activities and participates in the negative regulation of transcription mediated by RNA polymerase II. ATXN1L cooperates with Capicua (CIC) and ATXN1 in multimeric nuclear complexes, notably repressing Notch signaling by acting as a corepressor with CBF1. This protein plays regulatory roles in learning, memory, and social behavior, and is involved in development of the nervous system[2][3]. Unlike ATXN1, it does not encode a polyglutamine (polyQ) tract, but shares key structural domains with ATXN1 (e.g., AXH domain) important for protein-protein interactions[1][2]. While ATXN1L can suppress ATXN1-mediated cytotoxicity in spinocerebellar ataxia type 1, its primary functions are regulatory and it is not considered a direct therapeutic target[2][3]. The gene is associated with some CNS tumor types, but no approved drugs or biomarkers specifically target or monitor ATXN1L[2].
Not applicable; no drugs directly target ATXN1L or act through its modulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ataxin-1-like (ATXN1L).